Keywords: revenues, down, alexion, shrinking, deal, usa, pharmaceuticals
Revenues down at Alexion on shrinking P&G deal
Article | 16 June 2003
The USA's Alexion Pharmaceuticals has reported revenues of $167,000 for the fiscal third quarter ended April 30, 2003, compared with $539,000 during the like, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
